Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib  + letrozole: results from MONALEESA-2

ConclusionsHRQoL was consistently maintained from baseline in postmenopausal women with HR+, HER2 − advanced breast cancer receiving ribociclib plus letrozole and was similar to that observed in the placebo plus letrozole arm. Together with the improved clinical efficacy and manageable safety profile, these PRO results provide additional support for the benefit of ribociclib plus letrozole in this patient population.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research